PATENT CLAIM ANALYSIS

Application Number: 15756824
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
Provided are a monoclonal antibody specific for BQ323636.1, and its use for prediction of tamoxifen resistance in breast cancer patients.

Claim (Index 13):
A method of determining tamoxifen resistance in a subject with cancer, comprising:\n (a) obtaining a tumor sample from the subject; (b) determining in the sample a level of expression for a splice variant of NCOR2, wherein the splice variant is characterized by an exon 11 deletion during mRNA splicing resulting in an early translation stop codon and truncated protein; product, wherein said determining the expression level comprises using the antibody or antibody fragment of  claim 1 ; and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of the splice variant ofNCOR2, with respect to the control, indicates that the cancer is tamoxifen resistant.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 90.0
- Lexical Diversity: 1.04762
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14429657', '10591199', '13568145', '13177523', '12825057']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7058869450655616
- 35 USC 102 Novelty (BERT): 0.5124505056451516
- Combined Prediction Score: 0.6865433011235206
- Mean Citation Score: 266.799774
- Max Citation Score: 274.01337
- Similarity Product: 172.32968459226788

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test